Last reviewed · How we verify
Insulin therapy
Insulin therapy replaces or supplements the body's own insulin to regulate blood glucose by promoting glucose uptake into cells and storage as glycogen.
Insulin therapy replaces or supplements the body's own insulin to regulate blood glucose by promoting glucose uptake into cells and storage as glycogen. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus (when oral agents are insufficient), Gestational diabetes mellitus.
At a glance
| Generic name | Insulin therapy |
|---|---|
| Also known as | insulin injection therapy |
| Sponsor | Shanghai Jiao Tong University School of Medicine |
| Drug class | Peptide hormone |
| Target | Insulin receptor (INSR) |
| Modality | Small molecule |
| Therapeutic area | Endocrinology / Diabetes |
| Phase | Phase 3 |
Mechanism of action
Insulin is a peptide hormone that binds to insulin receptors on cell surfaces, facilitating glucose transport into muscle, fat, and liver cells. This lowers blood glucose levels and enables cells to utilize glucose for energy or store it as glycogen. Insulin therapy is used when the pancreas cannot produce sufficient insulin endogenously, as in type 1 diabetes or advanced type 2 diabetes.
Approved indications
- Type 1 diabetes mellitus
- Type 2 diabetes mellitus (when oral agents are insufficient)
- Gestational diabetes mellitus
Common side effects
- Hypoglycemia
- Weight gain
- Injection site reactions
- Lipodystrophy
Key clinical trials
- Trial of the Combination of Alpha-Lipoic Acid and Mirabegron in Women and in Men With Obesity (PHASE2)
- Risk Assessment of Pancreatic Islet Autoimmunity in Patients With AITD
- Prebiotics, Gut Microbiota, and Cardiometabolic Health (NA)
- Permissive Versus Strict Intrapartum Glucose Management in Type 1 Diabetes (PRISM-T1D) (PHASE4)
- Impact on Birth Weight of Two Therapeutic Strategies (Insulin Therapy From the Beginning of Pregnancy vs. Insulin Therapy Initiated According to Fetal Growth Evaluated by Ultrasonography Measurements) in Pregnant Women With Monogenic Diabetes (NA)
- ALXN2420 Versus Placebo in Combination With Somatostatin Analogs in Participants With Acromegaly (PHASE2)
- cfMSC Therapy for Diabetes (PHASE1, PHASE2)
- IMPACT-MACS: Adrenalectomy vs Semaglutide for Metabolic Outcomes in Mild Autonomous Cortisol Secretion (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Insulin therapy CI brief — competitive landscape report
- Insulin therapy updates RSS · CI watch RSS
- Shanghai Jiao Tong University School of Medicine portfolio CI